Published in Eur J Cancer Clin Oncol on November 01, 1984
Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev (2012) 6.12
Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer (1994) 0.96
Nerve growth factor/nuclear factor-kappaB pathway as a therapeutic target in breast cancer. J Cancer Res Clin Oncol (2008) 0.83
Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Res (2013) 0.83
Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. Br J Cancer (1987) 0.81
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy. Br J Cancer (2010) 0.80
A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen. BMC Syst Biol (2012) 0.79
Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med (1997) 6.55
Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J (1995) 6.03
Telomere maintenance by recombination in human cells. Nat Genet (2000) 5.14
Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res (1999) 4.24
Expression and amplification of cyclin genes in human breast cancer. Oncogene (1993) 3.79
Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet (1997) 3.56
Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem (1997) 2.40
Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A (1994) 2.29
Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet (2003) 2.26
Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer (2003) 2.06
Progestin regulation of cellular proliferation. Endocr Rev (1990) 2.04
Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol (2001) 1.99
c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol (1998) 1.97
The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit. Hum Mol Genet (1997) 1.97
Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res (1991) 1.88
Telomere dynamics and telomerase activity in in vitro immortalised human cells. Eur J Cancer (1997) 1.87
Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol (1995) 1.85
Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res (2001) 1.77
Prolactin controls mammary gland development via direct and indirect mechanisms. Dev Biol (1999) 1.70
Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res (2000) 1.70
Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol (1993) 1.65
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res (1983) 1.65
Human bronchial epithelial cells with integrated SV40 virus T antigen genes retain the ability to undergo squamous differentiation. Differentiation (1988) 1.64
The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia (2001) 1.60
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer (2009) 1.57
Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs. Oncogene (1998) 1.56
Cloning and characterization of GRB14, a novel member of the GRB7 gene family. J Biol Chem (1996) 1.52
SV40-induced immortalization of human cells. Crit Rev Oncog (1994) 1.51
Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol (1989) 1.51
Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol (1983) 1.49
Telomere length dynamics in telomerase-positive immortal human cell populations. Exp Cell Res (1998) 1.47
The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol (2012) 1.46
Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res (1998) 1.45
Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene (1994) 1.44
Telomere maintenance mechanisms and cellular immortalization. Curr Opin Genet Dev (1999) 1.43
Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem (1998) 1.43
Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol (1998) 1.42
Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene (2007) 1.42
Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res (2001) 1.40
Signaling pathways and structural domains required for phosphorylation of EMS1/cortactin. Cancer Res (1999) 1.39
Strontium phosphate transfection of human cells in primary culture: stable expression of the simian virus 40 large-T-antigen gene in primary human bronchial epithelial cells. Mol Cell Biol (1987) 1.39
Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res (1999) 1.39
Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Res (1985) 1.37
Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep (1982) 1.37
Mammalian stanniocalcins and cancer. Endocr Relat Cancer (2003) 1.35
Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol (1995) 1.35
A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem (2000) 1.34
Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids. Oncogene (1999) 1.34
Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res (2001) 1.32
Methylation of the human telomerase gene CpG island. Cancer Res (2000) 1.31
Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol (1991) 1.30
A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol (1995) 1.30
Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res (1987) 1.30
High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature (1980) 1.29
Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. Oncogene (2007) 1.28
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res (2000) 1.26
Characteristics of tumor cell bioactivity in oncogenic osteomalacia. Mol Cell Endocrinol (1996) 1.25
Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol (2000) 1.22
Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol (1998) 1.20
A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer (2006) 1.15
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene (1998) 1.15
Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene (2009) 1.15
Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer (2011) 1.15
A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes. Oncogene (2009) 1.15
A new human breast carcinoma cell line (PMC42) with stem cell characteristics. III. Hormone receptor status and responsiveness. J Natl Cancer Inst (1984) 1.14
Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res (1998) 1.13
Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene (1994) 1.12
DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer (2008) 1.11
Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. Biochem J (2000) 1.10
Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes. J Biol Chem (1997) 1.10
Correction of the copper transport defect of Menkes patient fibroblasts by expression of the Menkes and Wilson ATPases. J Biol Chem (1998) 1.10
Assignment of SV40-immortalized cells to more than one complementation group for immortalization. Exp Cell Res (1993) 1.10
Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res (1992) 1.10
Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer (2000) 1.09
Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7. J Biol Chem (1997) 1.08
Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res (1983) 1.08
p16(INK4a) and the control of cellular proliferative life span. Carcinogenesis (1999) 1.08
EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene (1997) 1.08
Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat (1994) 1.07
Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab (1997) 1.07
Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res (1997) 1.06
Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene (2012) 1.06
EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene (1998) 1.05
Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells. Oncogene (1998) 1.04
Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res (1996) 1.04
Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int J Cancer (1995) 1.04
Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells. Int J Cancer (1997) 1.03
Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein. Oncogene (1998) 1.03
Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res (2000) 1.02
Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro. Cancer Res (1983) 1.02
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br J Cancer (2008) 1.02
Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res (2001) 1.02
Cell cycle control by steroid hormones. Semin Cancer Biol (1994) 1.02
Germ-line splicing mutation of the p53 gene in a cancer-prone family. Cell Growth Differ (1992) 1.01
Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer (1996) 1.00